Bluebird bio (BLUE) Drops 12.89% on June 23

Equities Staff  |

Bluebird bio Inc (NASDAQ: BLUE) has fallen $0.575 (12.89%) and is currently sitting at $3.92, as of 11:50:02 est on June 23.

6,736,722 shares exchanged hands.

The Company has increased 28.16% over the last 5 days and shares have risen 39.38% over the last 30 days.

Bluebird bio expects its next earnings on 2022-08-09.

For technical charts, analysis, and more on Bluebird bio visit the company profile.

About Bluebird bio Inc

bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

To get more information on Bluebird bio Inc and to follow the company's latest updates, you can visit the company's profile page here: Bluebird bio Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content